Back to News
Market Impact: 0.3
Ascentage's Lisaftoclax Combination Gets China's Breakthrough Designation For Blood Cancer
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationProduct Launches
China's Center for Drug Evaluation granted breakthrough therapy designation to Ascentage Pharma's lisaftoclax combination with acalabrutinib for adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma. The designation is a positive regulatory development; no financial figures or market reaction were reported.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
AAPG0.70
More News
- New Mexico took on Meta alone and won a $25 billion judgment over Facebook’s privacy violations
- Meta ordered to pay $25 billion in case related to Cambridge Analytica scandal
- Judge orders Meta to pay $25bn in fines for Facebook privacy violations
- Sovereign wealth funds' China and Hong Kong investments surge 190% after a bruising slump
- Meta ordered to pay $25 billion in penalties over the Cambridge Analytica scandal
- Meta ordered to pay $25 billion penalty in New Mexico Cambridge Analytica case
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Weekly Update: Live Event Center, In-App Documents, and Faster Transcripts
- How to Automate Equity Research Workflows: A Control-First Guide